Skip to main content
Explore URMC

Jonathan W. Friedberg, M.D., M.M.Sc.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

Administrative: (585) 275-4911

Office: (585) 275-5823

Fax: (585) 273-5761

Social Links


URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Settings

Cancer, Hospital Medicine


As Director of the Wilmot Cancer Institute, I seek to provide the highest level of compassionate care for patients, ensuring access to novel treatments and clinical trials whenever possible. My background brings the entire continuum of lymphoma experience to patients, from diagnosis through all treatments including autologous stem cell transplantation, CAR-T cell interventions, novel agents, and survivorship.

We have built an incredibly strong team in Rochester to care for patients with lymphoma that is absolutely first rate and internationally recognized. We have expertise in hematopathology, radiation oncology, dermatology, and neurology, in addition to hematology and medical oncology. Driving this team toward excellence – and seeing our success – is highly rewarding.

Lymphoma is a complex set of diseases that can affect any organ system and I was drawn to that challenge. Our understanding of blood cancers in general, and specifically lymphoma, has enabled us to cure a subset of patients – and that also attracted me to this specialty. Happily, this fraction of cured patients has substantially increased during my 20-plus years in this field. Since lymphoma can affect anyone – males, females, young patients, older patients, and all ethnicities – I am rewarded by the interaction with a variety of patients.

My practice team includes Anna Morrison, R.N., Kerri Hugelmaier, N.P.

Conditions I Treat:

- Non-Hodgkin lymphoma
- Hodgkin lymphoma
- Waldenstrom macroglobulinemia
- Chronic lymphocytic leukemia

Professional Background

Jonathan W. Friedberg, M.D., is Director of the James P. Wilmot Cancer Institute Director of Hematological Malignancies Clinical Research, and the Samuel Durand Professor of Medicine at the University of Rochester Medical Center. He is a driving force behind the operations of Wilmot’s clinical and research programs, leading a team of associate directors who help make decisions surrounding Wilmot’s clinical, research, education, and community outreach missions.

Dr. Friedberg serves as the editor-in-chief of the Journal of Clinical Oncology (JCO), the flagship journal of the American Society of Clinical Oncology (ASCO). He began this five-year term in June 2021. Prior to his editor-in-chief role, he served as associated editor of JCO. He has also served as a reviewer and on editorial boards for a number of medical journals.

Friedberg is a chair of the lymphoma committee in the SWOG group of the NCI National Clinical Trials Network and is an independently R01-funded investigator in the field of lymphoid malignancies.

Dr. Friedberg received his medical degree from Harvard Medical School. His postgraduate training included an internship and residency at Massachusetts General Hospital. He also completed a medical oncology and hematology fellowship at Dana-Farber/Partners Cancer Care in Boston. Dr. Friedberg also has an M.M.Sc. degree from Harvard Medical School in clinical investigation. He holds subspecialty certification in Medical Oncology and Hematology.

His research interests focus on development of novel therapies for patients with lymphoma. He formerly received a Scholar in Clinical Research award from the Leukemia & Lymphoma Society, based upon his work with an oral inhibitor of a protein called Syk, which demonstrated efficacy in the treatment of several different forms of lymphoma. He is currently funded as PI of the ILyAD trial, evaluating patients with follicular lymphoma receiving rituximab with a vitamin D intervention. As chair of SWOG, he is co-leader of the current North American intergroup effort in advanced stage Hodgkin lymphoma. He is also a founding member of the Lymphoma Epidemiology of Outcomes Consortium.



  • Hematology - American Board of Internal Medicine


MD | Children's Hospital Harvard Medical (USA)

Post-doctoral Training & Residency

07/01/1997 - 06/01/1999
Fellowship in Hematology & Oncology at Dana-Farber Cancer Institute

07/01/1995 - 06/01/1997
Residency in Internal Medicine at Massachusetts General Hospital

07/01/1994 - 06/30/1995
Internship in Internal Medicine at Massachusetts General Hospital

VIEW ALL expand_more


Faculty Academic Mentoring Award
Sponsor: University of Rochester School of Medicine and Dentistry
Location: University of Rochester

2008 - 2008
Scholar in Clinical Research
Sponsor: Leukemia and Lymphoma Society

2008 - 2008
America's Top Doctors Selection

2007 - 2007
Jacob Gitelman Award
Sponsor: Gilda's Club and Cancer Action
Location: Rochester, NY

2004 - 2006
Lawrence A. Kohn Senior Teaching Fellow
Sponsor: Institute of Medicine
Location: Outstanding Teaching Contributions, Department of Medicine, Univ

2003 - 2003
Clinical Investigator Career Development Award
Sponsor: Lymphoma Research Foundation

2001 - 2003
Clinical Oncology Research Fellowship " Immunotherapy of Hodgkin's Disease"
Sponsor: Berlex Oncology Foundation

2001 - 2003
Rising stars program for innovative research
Sponsor: Dunkin Donuts and Dana-Farber Cancer Institute Department of Adu

VIEW ALL expand_more

Clinical Trials

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (ADCETRIS) Plus AVD in Patients (Age >/= 12 Years) With Newley Diagnosed Advanced Stage Classical Hodgkin Lymphoma (S1826),A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (ADCETRIS) Plus AVD in Patients (Age >/= 12 Years) With Newley Diagnosed Advanced Stage Classical Hodgkin Lymphoma (S1826)

Lead Researcher: Jonathan W Friedberg MD

This phase III trial compares immunotherapy drugs (nivolumab or brentuximab vedotin) when given with combination chemotherapy in treating patients with newly diagnosed stage III or IV classic Hodgkin lymphoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to cancer cells in a targeted way and delivers vedotin to kill them. Chemotherapy drugs, such as doxorubicin, vinblastine, and dacarbazine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The addition of nivolumab or brentuximab vedotin to combination chemotherapy may shrink the cancer or extend the time without disease symptoms coming back.

View Study Details


Journal Articles

Stephens DM, Li H, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, Song JY, LeBlanc ML, Smith SM, Persky DO, Friedberg JW. "Extranodal presentation in limited stage diffuse large B-cell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001." Haematologica.. 2022 Jul 14; Epub 2022 Jul 14.

Ansell SM, Radford J, Connors JM, D?ugosz-Danecka M, Kim WS, Gallamini A, Ramchandren R, Friedberg JW, Advani R, Hutchings M, Evens AM, Smolewski P, Savage KJ, Bartlett NL, Eom HS, Abramson JS, Dong C, Campana F, Fenton K, Puhlmann M, Straus DJ, . "Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma." The New England journal of medicine.. 2022 Jul 13; Epub 2022 Jul 13.

Rutherford SC, Yin J, Pederson L, Perez Burbano G, LaPlant B, Shadman M, Li H, LeBlanc ML, Kenkre VP, Hong F, Blum KA, Dockter T, Martin P, Jung SH, Grant B, Rosenbaum C, Ujjani C, Barr PM, Unger JM, Cheson BD, Bartlett NL, Kahl B, Friedberg JW, Mandrekar SJ, Leonard JP. "Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2022 Jul 5; :JCO2102301. Epub 2022 Jul 05.

Books & Chapters

Chapter Title: Lymphocyte-predominant Hodgkin's lymphoma. Evidence-based Hematology
Book Title: Evidence-based Hematology
Author List: McMahon B, Friedberg JW
Published By: Evidence based Hematology 2008

Chapter Title: Diffuse Large B cell lymphoma
Book Title: Hematology/Oncology Clinics of North America
Author List: Friedberg JW, Fisher RI
Published By: Hematology/Oncology Clinics of North America 2008

Chapter Title: Monoclonal antibodies in lymphoma: the first decade.
Book Title: Seminars in Hematology
Author List: Link BK and Friedberg JW
Published By: Seminars in Hematology 2008